Recurrent Mantle Cell Lymphoma (DBCOND0028615)

Identifiers

Synonyms

Recurrent Lymphoma, Mantle-Cell / Mantle Cell Lymphoma Recurrent

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT02419560	Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL	Ibrutinib Venetoclax	treatment	1	completed
NCT04234061	Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma	Ibrutinib Tisagenlecleucel	treatment	2	active_not_recruiting
NCT02086591	A Phase II Study of Doxycycline in Relapsed NHL	Doxycycline	treatment	2	terminated
NCT05645744	Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.	MB-102 CD123 CAR	Not Available	Not Available	terminated
NCT05360238	Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL	No drug interventions	treatment	1 / 2	terminated
NCT01322776	Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma	Bortezomib Cyclophosphamide Fludarabine	treatment	1 / 2	unknown_status
NCT05453396	Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies	Loncastuximab tesirine	treatment	2	recruiting
NCT06343376	Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies	Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT01955499	Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	Ibrutinib Lenalidomide	treatment	1	active_not_recruiting
NCT03946878	Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma	Acalabrutinib Tyrosine Venetoclax	treatment	2	active_not_recruiting
NCT04578600	CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma	Azacitidine Lenalidomide Obinutuzumab	treatment	1	active_not_recruiting
NCT04659044	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	Hyaluronidase (human recombinant) Polatuzumab vedotin Rituximab Venetoclax	treatment	2	terminated
NCT04872413	Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening With Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial	No drug interventions	screening	Not Available	recruiting
NCT00489203	Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer	Beclomethasone dipropionate Methotrexate Tacrolimus	supportive_care	2	completed
NCT00703664	Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma	Bortezomib Bortezomib D-mannitol Vorinostat	treatment	2	completed
NCT00023764	Bortezomib in Treating Patients With Lymphoproliferative Disorders	Bortezomib Bortezomib D-mannitol	treatment	2	completed
NCT01233921	Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer	Palifermin	supportive_care	Not Available	completed
NCT01748721	MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma	Ontuxizumab	treatment	1	completed
NCT00082784	Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms	Alvocidib Bortezomib	treatment	1	completed
NCT01921387	Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies	Beta-D-Glucose Carmustine Cytarabine Etoposide Mechlorethamine	treatment	1 / 2	completed
NCT01116154	Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma	Lenalidomide Vorinostat	treatment	1	terminated
NCT00006251	Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1 / 2	completed
NCT02568553	Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma	Blinatumomab Lenalidomide Muromonab	treatment	1	active_not_recruiting
NCT00890747	Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy	Sunitinib	treatment	1	completed
NCT00293345	3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma	Gemcitabine Triapine	treatment	1	completed
NCT01258998	Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma	No drug interventions	treatment	2	completed
NCT00054483	Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction	Bortezomib Bortezomib D-mannitol	basic_science	1	completed
NCT04635683	Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	Lenalidomide Ublituximab Umbralisib	treatment	1	withdrawn
NCT00608361	Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery	Dasatinib	treatment	1	completed
NCT01045928	Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma	Lenalidomide Rituximab	treatment	1	terminated
NCT01129193	AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma	AR-42	treatment	1	completed
NCT01177371	High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma	Busulfan Cyclophosphamide Cyclosporine Methotrexate Methylprednisolone Methylprednisolone hemisuccinate	treatment	2	completed
NCT00110071	Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma	Fludarabine	treatment	1	completed
NCT01558778	Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	Not Available	withdrawn
NCT01254578	Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers	Lenalidomide	treatment	1	completed
NCT03579888	CD19-Specific T Cells Post AlloSCT	Cyclophosphamide Fludarabine	treatment	1	terminated
NCT00082888	Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma	Tipifarnib	treatment	2	completed
NCT00117988	17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma	Tanespimycin	treatment	2	completed
NCT04205409	Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies	Nivolumab	treatment	2	active_not_recruiting
NCT01567709	Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma	Alisertib Vorinostat	treatment	1	completed
NCT00354185	PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma	Belinostat Tanespimycin	treatment	1	terminated
NCT00068315	Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia	Bortezomib Bortezomib D-mannitol Fludarabine Rituximab	treatment	1	completed
NCT00025415	Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction	Imatinib	treatment	1	completed
NCT01805037	Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas	Brentuximab vedotin Rituximab	treatment	1 / 2	terminated
NCT00118352	Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer	Alemtuzumab Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT00003970	Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma	Irinotecan	treatment	1	completed
NCT02685670	Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma	Cyclophosphamide Fludarabine	treatment	1 / 2	unknown_status
NCT01479842	Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma	Bendamustine Ibrutinib Rituximab Tyrosine	treatment	1	active_not_recruiting
NCT00723099	Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	Cyclophosphamide Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT01815749	Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma	No drug interventions	treatment	1	active_not_recruiting
NCT04995536	CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL	No drug interventions	treatment	1	withdrawn
NCT00073918	Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Cyclophosphamide Etoposide	treatment	2	completed
NCT00058019	Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma	Ixabepilone Patupilone	treatment	2	completed
NCT02240719	Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer	Bendamustine Everolimus	treatment	1	completed
NCT02049541	Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma	Buparlisib Rituximab	treatment	1	completed
NCT02736617	Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma	Ibrutinib Obinutuzumab	treatment	2	completed
NCT01839916	Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Therapeutic allogeneic lymphocytes	treatment	2	completed
NCT00078858	Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1 / 2	completed
NCT01475058	CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant	Allogeneic cytomegalovirus-specific cytotoxic T lymphocytes	treatment	1 / 2	completed
NCT00014235	Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	Not Available	completed
NCT05432635	Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma	Modified vaccinia ankara	treatment	1	recruiting
NCT01035463	Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma	Beta-D-Glucose Carmustine Cytarabine Etoposide Lenalidomide Mechlorethamine Rituximab	treatment	1 / 2	completed
NCT01093586	Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Cyclophosphamide Cyclosporine Methylprednisolone Methylprednisolone hemisuccinate Mycophenolate mofetil	treatment	2	completed
NCT02051257	Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma	No drug interventions	treatment	1	active_not_recruiting
NCT00003166	Bryostatin and Vincristine in B-Cell Malignancies	Bryostatin 1 Sulfate ion Vincristine	treatment	1	completed
NCT01686165	Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL	Belinostat Rituximab	treatment	2	completed
NCT01158274	RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors	Capecitabine RG-4733	treatment	1	completed
NCT00026182	Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma	Edodekin alfa Natural Killer Cell Rituximab	treatment	2	completed
NCT01529827	Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Fludarabine Melphalan Methotrexate Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00058227	Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma	Alvocidib Fludarabine Rituximab	treatment	1	completed
NCT00789776	Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer	Cyclophosphamide Fludarabine Mycophenolate mofetil Natural Killer Cell Tacrolimus	treatment	1 / 2	completed
NCT00089076	MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma	Ipilimumab	treatment	1 / 2	terminated
NCT03185494	Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22	No drug interventions	treatment	1 / 2	unknown_status
NCT00098891	MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas	Entinostat Isotretinoin	treatment	1	completed
NCT01199562	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant	Foscarnet Ganciclovir Valganciclovir	Not Available	Not Available	completed
NCT04007029	Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	Cyclophosphamide Fludarabine Tocilizumab	treatment	1	recruiting
NCT01864889	Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19	No drug interventions	treatment	Not Available	unknown_status
NCT01381692	Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma	Bortezomib Bortezomib D-mannitol Dexamethasone Menthol Rituximab Sirolimus Temsirolimus	treatment	1 / 2	completed
NCT00010192	Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer	Aldesleukin Rituximab	treatment	1	completed
NCT00101244	SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma	Ispinesib	treatment	1	terminated
NCT02285244	Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation	Sotrastaurin	treatment	2	withdrawn
NCT00553644	Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma	Bortezomib Bortezomib D-mannitol Lenalidomide	treatment	2	completed
NCT00086944	Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma	Carboplatin Etoposide Filgrastim Ifosfamide Pegfilgrastim Rituximab	treatment	1 / 2	completed
NCT01159067	Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload	Deferasirox	supportive_care	2	terminated
NCT00033267	CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma	Menthol Temsirolimus	treatment	2	completed
NCT01880567	Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma	Ibrutinib Rituximab	treatment	2	active_not_recruiting
NCT05910801	Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	Lenalidomide Tafasitamab Venetoclax	treatment	2	recruiting
NCT01735604	Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy	No drug interventions	treatment	1 / 2	unknown_status
NCT00049504	Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00060372	Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer	Ipilimumab Therapeutic allogeneic lymphocytes	treatment	1	completed
NCT00891072	Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	Carboplatin Isosorbide Paclitaxel	treatment	1	completed
NCT00040846	Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies	Alemtuzumab Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT00060112	Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma	Gemcitabine	treatment	1	terminated
NCT01267812	Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation	Bortezomib Bortezomib D-mannitol Rituximab	treatment	2	completed
NCT04484012	Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	Acalabrutinib Tyrosine	treatment	2	recruiting
NCT00003210	Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease	Edodekin alfa Natural Killer Cell	treatment	2	completed
NCT02652910	Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma	No drug interventions	treatment	1 / 2	unknown_status
NCT00017381	Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma	Cyclophosphamide Filgrastim Rituximab	treatment	0	completed
NCT00408681	Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant	Lithium carbonate	supportive_care	Not Available	completed
NCT02420795	Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Dordaviprone	treatment	1 / 2	terminated
NCT01719250	Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	Buparlisib	treatment	0	completed
NCT01523223	Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies	Therapeutic allogeneic lymphocytes	treatment	1	completed
NCT01678443	Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies	Indium Yttrium Y-90	treatment	1	terminated
NCT01408043	Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma	Etoposide Filgrastim Plerixafor	treatment	Not Available	terminated
NCT01075321	Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma	Everolimus Lenalidomide	treatment	1 / 2	completed
NCT00003502	Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma	Antineoplaston A10	treatment	2	withdrawn
NCT01326702	Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors	Bendamustine Rituximab Veliparib	treatment	1 / 2	completed
NCT02281279	Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma	Lenalidomide Rituximab Romidepsin	treatment	1 / 2	withdrawn
NCT00538187	Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma	Bortezomib Bortezomib D-mannitol Obatoclax	treatment	1	terminated
NCT06191887	B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies	Bendamustine Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT02869633	Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant	Ibrutinib	treatment	2	completed
NCT00918333	Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma	Everolimus Panobinostat	treatment	1 / 2	completed
NCT02572453	Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL	Onalespib	treatment	2	terminated
NCT01959477	Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant	Busulfan Cyclophosphamide Etoposide	treatment	0	completed
NCT01261247	Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	Panobinostat	treatment	2	completed
NCT03219047	Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma	Ibrutinib	treatment	0	completed
NCT01044745	Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Cyclophosphamide Fludarabine Mycophenolate mofetil Rituximab Tacrolimus	treatment	2	terminated
NCT01527045	Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies	Atorvastatin Cyclosporine Fludarabine Mycophenolate mofetil	prevention	2	completed
NCT00343798	A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies	Cyclophosphamide Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1	completed
NCT00058305	Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation	Bryostatin 1 Sulfate ion Vincristine	treatment	2	completed
NCT00096005	Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas	Bortezomib Bortezomib D-mannitol Tanespimycin	treatment	1	terminated
NCT01812005	Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	Alisertib Rituximab	treatment	2	terminated
NCT04047797	Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma	Ixazomib Rituximab	treatment	2	active_not_recruiting
NCT00799461	Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications	No drug interventions	supportive_care	3	completed
NCT00711828	Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma	Bortezomib Cyclophosphamide Dexamethasone Rituximab	treatment	2	completed
NCT01769911	Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma	6-O-benzylguanine Carmustine Cytarabine Etoposide Melphalan	treatment	Not Available	withdrawn
NCT00089011	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer	Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00499811	Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction	Vorinostat	treatment	1	completed
NCT00089271	17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas	Alvespimycin	treatment	1	completed
NCT04990778	Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma	Eprenetapopt Venetoclax	treatment	2	withdrawn
NCT00856388	Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Fludarabine Melphalan	treatment	Not Available	completed
NCT00769288	FAU in Treating Patients With Advanced Solid Tumors or Lymphoma	No drug interventions	treatment	1	completed
NCT02168907	CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	Bendamustine Devimistat Lipoic acid Rituximab	treatment	1	terminated
NCT02721407	Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients	No drug interventions	treatment	1	unknown_status
NCT02037256	Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma	Bortezomib Bortezomib D-mannitol Filgrastim	treatment	Not Available	completed
NCT00348985	PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas	Belinostat Bortezomib Bortezomib D-mannitol	treatment	1	completed
NCT03147885	Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma	Escitalopram Selinexor	treatment	1 / 2	recruiting
NCT01588015	Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	1	completed
NCT00621452	Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma	Aldesleukin Cyclophosphamide	treatment	1	completed
NCT03097770	Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20	No drug interventions	treatment	1 / 2	completed
NCT01076270	Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Filgrastim Plerixafor	treatment	Not Available	terminated
NCT00118170	Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function	Sorafenib	treatment	1	completed
NCT00601718	Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	Carboplatin Etoposide Ifosfamide Rituximab Vorinostat	treatment	1 / 2	completed
NCT01231919	MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia	No drug interventions	treatment	1	completed
NCT01658319	Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies	Fludarabine Methoxyamine	treatment	1	completed
NCT01695941	Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma	Alisertib Bortezomib Bortezomib D-mannitol Rituximab	treatment	1	active_not_recruiting
NCT00004241	17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma	Tanespimycin	treatment	1	completed
NCT01318317	Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma	Filgrastim Plerixafor Rituximab	treatment	1 / 2	active_not_recruiting
NCT01865617	Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia	No drug interventions	treatment	1 / 2	completed
NCT02109224	Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection	Ibrutinib	treatment	1	terminated
NCT00109824	Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	2'-Deoxycytidine Decitabine Valproic acid	treatment	1	completed
NCT01028716	Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Cyclophosphamide Filgrastim Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	terminated
NCT03015896	Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma	Lenalidomide Nivolumab	treatment	1 / 2	active_not_recruiting
NCT00003196	Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma	Cyclosporine Mycophenolate mofetil Therapeutic allogeneic lymphocytes	treatment	Not Available	completed
NCT01110135	Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma	Bendamustine Dexamethasone Etoposide Filgrastim	treatment	2	completed
NCT00054639	Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma	Rituximab	treatment	2	completed
NCT01769222	Ipilimumab and Local Radiation for Selected Solid Tumors	Ipilimumab	treatment	1	terminated
NCT00253630	Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma	Vorinostat	treatment	2	completed
NCT01029366	CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy	Tisagenlecleucel	treatment	1	completed
NCT01273766	Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies	Deferasirox	supportive_care	2	completed
NCT00383565	FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Romidepsin	treatment	2	terminated
NCT02950220	Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	Ibrutinib Pembrolizumab	treatment	1	completed
NCT00278382	Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma	Sorafenib	treatment	2	completed
NCT00458731	Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma	Bevacizumab Cediranib	treatment	1	completed
NCT03035331	Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma	Corynebacterium diphtheriae Pembrolizumab Streptococcus pneumoniae type 1 capsular polysaccharide antigen Streptococcus pneumoniae type 14 capsular polysaccharide antigen Streptococcus pneumoniae type 18c capsular polysaccharide antigen Streptococcus pneumoniae type 19a capsular polysaccharide antigen Streptococcus pneumoniae type 19f capsular polysaccharide antigen Streptococcus pneumoniae type 23f capsular polysaccharide antigen Streptococcus pneumoniae type 3 capsular polysaccharide antigen Streptococcus pneumoniae type 4 capsular polysaccharide antigen Streptococcus pneumoniae type 5 capsular polysaccharide antigen Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigen Streptococcus pneumoniae type 6b capsular polysaccharide antigen Streptococcus pneumoniae type 7f capsular polysaccharide antigen Streptococcus pneumoniae type 9v capsular polysaccharide antigen	treatment	1 / 2	active_not_recruiting
NCT00006473	Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Oxaliplatin	treatment	2	completed
NCT00016094	S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma	Bevacizumab	treatment	2	completed
NCT01397591	Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma	Bortezomib Bortezomib D-mannitol Ofatumumab	treatment	2	terminated
NCT00275080	Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia	2'-Deoxycytidine Decitabine Vorinostat	treatment	1	completed
NCT00438880	Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma	Agatolimod Rituximab	treatment	1 / 2	completed
NCT02153580	Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia	Bendamustine Beta-D-Glucose Cyclophosphamide Etoposide Fludarabine	treatment	1	active_not_recruiting
NCT03277729	A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	Cyclophosphamide Fludarabine	treatment	1 / 2	active_not_recruiting
NCT05936229	Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy	Interferon beta-1a Water	prevention	1 / 2	withdrawn
NCT00867529	Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma	Rituximab	treatment	2	completed
NCT00119392	Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Cyclosporine Fludarabine Mycophenolate mofetil Rituximab	treatment	2	completed
NCT02303392	Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma	Escitalopram Ibrutinib Selinexor	treatment	1	unknown_status
NCT02706392	Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies	No drug interventions	treatment	1	terminated
NCT00288067	Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma	Fenretinide Rituximab	treatment	1 / 2	terminated
NCT03440567	Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma	Avelumab Carboplatin Cyclophosphamide Etoposide Ibrutinib Ifosfamide Rituximab Utomilumab	treatment	1	active_not_recruiting
NCT00109967	CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma	Menthol Rituximab Temsirolimus	treatment	2	completed
NCT04054167	Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma	No drug interventions	treatment	2	recruiting
NCT00536601	High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors	Busulfan Carboplatin Carmustine Cyclophosphamide Etoposide Melphalan Thiotepa	treatment	Not Available	completed
NCT00105001	Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer	Fludarabine Mycophenolate mofetil Sirolimus Tacrolimus	treatment	2	completed
NCT04939272	Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	Copanlisib Venetoclax	treatment	1 / 2	active_not_recruiting
NCT00103272	17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer	Bortezomib Bortezomib D-mannitol Tanespimycin	treatment	1	terminated
NCT03479268	Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	Ibrutinib Pevonedistat	treatment	1	active_not_recruiting
NCT00795769	Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant	Ondansetron	supportive_care	2	completed
NCT01238146	Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	Bendamustine Obatoclax Rituximab	treatment	1 / 2	withdrawn
NCT01897012	Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas	Alisertib Romidepsin	treatment	1	completed
NCT01427881	Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies	Busulfan Cyclophosphamide Cyclosporine Fludarabine	treatment	2	completed
NCT01419795	Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant	Lenalidomide Rituximab	treatment	2	terminated
NCT00072514	Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies	Carboplatin Dexamethasone Gemcitabine Rituximab	treatment	2	completed
NCT01652014	Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	withdrawn
NCT02159755	Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma	Ibrutinib Palbociclib	treatment	1	active_not_recruiting
NCT01789255	Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies	Cyclosporine Methotrexate Tacrolimus Vorinostat	supportive_care	2	completed
NCT00077155	Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma	Cilengitide	treatment	1	completed
NCT02489123	Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma	Enzalutamide	treatment	2	terminated
NCT00112723	Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma	Alvocidib	treatment	1 / 2	terminated